13F Holdings
中文EN

BEAM Beam Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745999 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY163.3%
TTM net income YoY74.1%
TTM EPS YoY80.0%
Revenue 3-yr CAGR21.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-267.7%
Net margin-73.0%
FCF margin-271.6%
EBITDA margin-252.6%

Returns

ROE-11.1%
ROA-8.3%
ROIC (approx.)-40.2%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets24.9%
Debt / equity0.11x
Current ratio13.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.63x
Accruals ratio21.8%
Payout ratio—
Capex / revenue6.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$139.74M$63.52M$377.71M$60.92M$51.84M
R&D expense$409.62M$367.56M$437.38M$311.59M$387.09M
SG&A expense$113.82M$111.53M$116.81M$87.81M$57.22M
Operating income-$383.69M-$415.57M-$176.49M-$338.48M-$392.46M
Pretax income-$79.99M-$376.70M-$131.16M-$260.18M-$370.64M
Income tax$0$39,000$1.37M$3.41M$0
Net income-$79.99M-$376.74M-$132.53M-$289.09M-$370.64M
EBITDA-$361.40M-$393.64M-$156.47M-$324.33M-$385.01M
EPS (basic)-0.81-4.58-1.72-4.13-5.77
EPS (diluted)-0.81-4.58-1.72-4.13-5.77
Weighted avg. shares (diluted)98.91M82.31M77.15M70.02M64.23M
Balance sheet
Cash & equivalents$294.94M$290.11M$435.89M$245.52M$572.74M
Short-term investments$950.27M$568.77M$753.98M$845.37M—
Current assets$1.27B$878.15M$1.21B$1.09B$1.27B
PP&E, net$104.50M$111.41M$124.96M$115.62M$84.26M
Total assets$1.48B$1.10B$1.46B$1.34B$1.47B
Current liabilities$96.94M$182.07M$205.56M$223.59M$213.44M
Total liabilities$242.82M$370.28M$478.38M$608.24M$647.72M
Shareholders' equity$1.24B$733.54M$981.33M$733.47M$826.74M
Shares outstanding101.75M83.63M81.63M71.28M68.39M
Cash flow statement
Operating cash flow-$345.10M-$347.25M-$149.19M$22.53M-$66.27M
Capital expenditure$14.95M$8.95M$33.73M$48.95M$46.81M
Free cash flow-$360.05M-$356.19M-$182.93M-$26.42M-$113.08M
Investing cash flow-$121.44M$185.01M$71.84M-$461.34M-$294.14M
Financing cash flow$478.05M$7.74M$276.45M$111.59M$756.14M
Depreciation & amortization$22.29M$21.93M$20.01M$14.15M$7.45M
Stock-based compensation$94.24M$120.66M$98.65M$84.32M$43.57M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.